South Korea’s Samsung Biologics Co., the world’s largest contract drugmaker, said on Tuesday it signed a contract manufacturing organization (CMO) deal with an unidentified European biopharmaceutical firm.
This deal is the company’s largest ever, representing 40% of last year’s full-year orders.
The contract runs through December 31, 2030. The client and product name weren’t disclosed due to confidentiality provisions.
Samsung Biologics said it broke the record just over three months after signing a $1.1 billion contract with an Asian pharmaceutical company last October.
Since its founding, the company’s cumulative orders total about $17.6 billion.
Samsung Biologics is building a fifth plant with an annual production capacity of 180,000 liters, which is expected to be operational in April.
After completion, it will have a total capacity of 784,000 liters per year, the company said.
By Jeong Min Nam
peux@hankyung.com
